Mainz Biomed Expands Commercial Footprint into Poland
May 31, 2023 03:01 ET
|
Mainz BioMed NV
Total addressable market in Poland is estimated at 21 million patients BERKELEY, Calif. and MAINZ, Germany, May 31, 2023 (GLOBE NEWSWIRE) -- Mainz Biomed NV (NASDAQ:MYNZ) (“Mainz Biomed” or the...
Mainz Biomed Processes First Patients from Colorectal Cancer Screening Campaign Through its Corporate Health Portal in Partnership with Zöeller-Kipper
May 24, 2023 03:01 ET
|
Mainz BioMed NV
Employees found the online patient portal, through which they ordered the ColoAlert® test, easy-to-use and convenient BERKELEY, Calif. and MAINZ, Germany, May 24, 2023 (GLOBE NEWSWIRE) --...
Mainz Biomed Announces First Quarter 2023 Financial Results and Provides Corporate Update
May 16, 2023 03:01 ET
|
Mainz BioMed NV
ColoAlert® Revenue Increases 152% Year Over Year BERKELEY, Calif. and MAINZ, Germany, May 16, 2023 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a...
Mainz Biomed Partners with Microba Life Sciences for the Development of PancAlert
May 10, 2023 03:01 ET
|
Mainz BioMed NV
Combination of DNA biomarkers with microbiome biomarkers has potential to enhance technical profile of novel pancreatic cancer screening test Joint research project to discover disease specific...
Mainz Biomed Announces Addition of Eurofins GeLaMed to its Growing Network of Lab Partners
May 03, 2023 03:01 ET
|
Mainz BioMed NV
Eurofins GeLaMed to provide test kit processing of ColoAlert® through Germany BERKELEY, Calif. and MAINZ, Germany, May 03, 2023 (GLOBE NEWSWIRE) -- Mainz Biomed NV (NASDAQ:MYNZ) (“Mainz Biomed” or...
Mainz Biomed to Participate in Digestive Disease Week 2023
May 01, 2023 03:01 ET
|
Mainz BioMed NV
BERKELEY, Calif. and MAINZ, Germany, May 01, 2023 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the...
Mainz Biomed to Commence Quarterly Reporting and Present at Equity Forum Spring Conference 2023 in Frankfurt, Germany
April 27, 2023 03:01 ET
|
Mainz BioMed NV
BERKELEY, Calif. and MAINZ, Germany, April 27, 2023 (GLOBE NEWSWIRE) -- Mainz Biomed NV (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the...
Mainz Biomed Announces Partnership with the Instituto de Microecologia to Expand ColoAlert® Commercialization in Spain and Portugal
April 26, 2023 03:01 ET
|
Mainz BioMed NV
BERKELEY, Calif. and MAINZ, Germany, April 26, 2023 (GLOBE NEWSWIRE) -- Mainz Biomed NV (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the...
Mainz Biomed Provides Full Year 2022 Financial Results
April 10, 2023 03:01 ET
|
Mainz BioMed NV
ColoAlert Revenue Increases 130% Year over Year Year End Cash Balance of $17.1 Million BERKELEY, Calif. and MAINZ, Germany, April 10, 2023 (GLOBE NEWSWIRE) -- Mainz Biomed N.V....
Mainz Biomed Expands Corporate Health Program for ColoAlert with the Addition of Three New Companies in Germany
April 04, 2023 03:01 ET
|
Mainz BioMed NV
BERKELEY, Calif. and MAINZ, Germany, April 04, 2023 (GLOBE NEWSWIRE) -- Mainz Biomed NV (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the...